CNTB - Connect and Simcere sign license agreement for autoimmune drug Rademikibart
2023-11-23 03:09:21 ET
More on Connect Biopharma
- Connect Biopharma stock rises on positive data from dermatitis mAb
- Connect Biopharma receives Nasdaq notification regarding minimum bid price deficiency
- Financial information for Connect Biopharma
For further details see:
Connect and Simcere sign license agreement for autoimmune drug Rademikibart